A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial

Randomized Controlled Trial

doi: 10.1136/ard.2009.121533. Epub 2010 May 28.

Affiliations

PMID: 20511606
DOI: 10.1136/ard.2009.121533

Randomized Controlled Trial

Maxime Dougados et al. Ann Rheum Dis. 2010 Aug.

Abstract

Objective: Inflammation at the entheses is a distinguishing feature of spondyloarthritis (SpA). Enthesitis at the heel is the most common location and is often chronic, refractory to standard treatment and may have socioeconomic consequences. The objective of this study was to investigate the efficacy of etanercept in refractory heel enthesitis related to SpA.

Methods: The present work was a 12-week, randomised, double-blind, placebo-controlled study compared etanercept with placebo in patients with SpA according to Amor's criteria, and heel enthesitis proven by MRI. The primary efficacy end point was the normalised net incremental area under the curve (AUC) between randomisation and week 12 for the patient's global assessment (PGA) of disease activity. Secondary end points included change from baseline in PGA, heel pain, the Western Ontario and McMaster Universities Osteoarthritis index (WOMAC) function subscale and improvement in enthesitis as measured by MRI.

Results: A total of 24 patients were randomised. Mean normalised net incremental AUC for PGA of disease activity over 12 weeks was significantly greater in the etanercept versus placebo group: -28.5 versus -11.1, respectively (p=0.029). Significant improvements were also reported in the etanercept versus placebo group for PGA, -37.6 versus -11.6 (p=0.007); heel pain, -36.7 versus -13.1 (p=0.022); and WOMAC function, -23.2 versus -7.8 (p=0.024). No significant changes were observed in the MRI findings between groups. No unexpected adverse events or changes in laboratory values or vital signs.

Conclusions: This trial is the first randomised placebo-controlled study of an anti-tumour necrosis factor (TNF) agent in refractory heel enthesitis in patients with SpA. It demonstrates that etanercept has a statistically significant and clinically relevant benefit in such patients. ClinicalTrials.gov identifier NCT00420303.

PubMed Disclaimer

Cited by

The Effect of Therapeutic Exercise and Local Cryotherapy on Lower Limb Enthesitis in Non-Radiographic Axial Spondyloarthritis: A Case Report.
Alito A, Talotta R, D'Amico V, Amato D, Milardi D, Capodaglio P. Alito A, et al. J Pers Med. 2024 Sep 28;14(10):1035. doi: 10.3390/jpm14101035. J Pers Med. 2024. PMID: 39452543 Free PMC article.
Korean treatment recommendations for patients with axial spondyloarthritis.
Seo MR, Yeo J, Park JW, Lee YA, Lee JH, Kang EH, Ji SM, Kwon SR, Kim SK, Kim TJ, Kim TH, Kim HW, Park MC, Shin K, Lee SH, Lee EY, Cha HS, Shim SC, Yoon Y, Lee SH, Lim JH, Baek HJ; Korean Society of Spondyloarthritis Research. Seo MR, et al. Korean J Intern Med. 2023 Sep;38(5):620-640. doi: 10.3904/kjim.2023.194. Epub 2023 Jul 24. Korean J Intern Med. 2023. PMID: 37482652 Free PMC article.
Korean treatment recommendations for patients with axial spondyloarthritis.
Seo MR, Yeo J, Park JW, Lee YA, Lee JH, Kang EH, Ji SM, Kwon SR, Kim SK, Kim TJ, Kim TH, Kim HW, Park MC, Shin K, Lee SH, Lee EY, Cha HS, Shim SC, Yoon Y, Lee SH, Lim JH, Baek HJ; Korean Society of Spondyloarthritis Research. Seo MR, et al. J Rheum Dis. 2023 Jul 1;30(3):151-169. doi: 10.4078/jrd.2023.0025. J Rheum Dis. 2023. PMID: 37476674 Free PMC article. Review.
Achilles enthesitis on physical examination leads to worse outcomes after 2 years of follow up in patients with ankylosing spondylitis from REGISPONSER-AS registry.
López-Medina C, Puche-Larrubia MÁ, Granados R, Ladehesa-Pineda L, Ruiz-Vilchez D, Ábalos-Aguilera MC, Font-Ugalde P, Collantes-Estévez E. López-Medina C, et al. Arthritis Res Ther. 2023 Jan 13;25(1):8. doi: 10.1186/s13075-023-02988-x. Arthritis Res Ther. 2023. PMID: 36639793 Free PMC article.
Peripheral spondyloarthritis and psoriatic arthritis sine psoriase: are we dealing with semantics or clinically meaningful differences?
Ziade N, Bou Absi M, Baraliakos X. Ziade N, et al. RMD Open. 2022 Nov;8(2):e002592. doi: 10.1136/rmdopen-2022-002592. RMD Open. 2022. PMID: 36332938 Free PMC article. Review.

A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial - PubMed (original) (raw)